George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCIR.L Regulatory News (CIR)

  • There is currently no data for CIR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

14 Apr 2020 07:30

RNS Number : 5304J
Circassia Pharmaceuticals Plc
14 April 2020
 

Director/PDMR Shareholding

Oxford, UK - 14 April 2020: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, today announces that on 9 April 2020, Ian Johnson, Executive Chairman of Circassia purchased 200,000 Ordinary Shares at a price of 22.85 pence per share, Michael Roller, Chief Financial Officer purchased 200,000 Ordinary Shares at a price of 22.683 pence per share and Jonathan Emms, Chief Operating Officer of Circassia, purchased 300,000 Ordinary Shares at a price of 23.2 pence per share.

Following these purchases, Ian Johnson holds 200,000 Ordinary Shares (0.05% of the issued share capital of the Company), Michael Roller holds 200,000 Ordinary Shares (0.05% of the issued share capital of the Company) and Jonathan Emms holds 600,000 Ordinary Shares (0.16% of the issued share capital of the Company).

Contacts

Circassia Pharmaceuticals plc

Ian Johnson Executive Chairman

Michael Roller Chief Financial Officer

c/o FTI Consulting

 

 

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel / Oliver Jackson

 

Tel: +44 (0)20 7418 8900

finnCap (Joint Broker)

Geoff Nash / Alice Lane

 

Tel: +44 (0) 20 7220 0500

Numis Securities (Joint Broker)

James Black / Duncan Monteith

 

Tel: +44 (0) 20 7260 1000

FTI Consulting

Simon Conway / Ciara Martin

Tel: +44 (0) 20 3727 1000

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

1. Ian Johnson

2. Michael Roller

3. Jonathan Emms

2.

Reason for the notification

a.

Position/status

1. Executive Chairman

2. Chief Financial Officer

3. Chief Operating Officer

b.

Initial notification

/Amendment

 

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Circassia Pharmaceuticals plc

b.

LEI

2138006YAT138TOGA556

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary Shares of 0.08p each

 

 

GB00BJVD3B28

b.

Nature of the transaction

Purchase of Ordinary Shares

 

c.

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

1. 22.85p

2. 22.683p

3. 23.2p

1. 200,000

2. 200,000

3. 300,000

d.

Aggregated information

· Aggregated volume

· Price

 

 

 

n/a

 

e.

Date of the transaction

2020-04-09

f.

Place of the transaction

London Stock Exchange, AIM

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGLGDSCDBDGGS
Date   Source Headline
18th Jan 20192:22 pmRNSBlock listing Interim Review
4th Jan 20191:48 pmRNSResult of General Meeting
4th Jan 20197:00 amRNSGeneral Meeting Business Update
31st Dec 20187:00 amRNSTotal Voting Rights
27th Dec 20187:00 amRNSHolding(s) in Company
17th Dec 20187:00 amRNSListing Rule 9.6.14(R) Disclosure
11th Dec 201812:10 pmRNSOption exercised for Tudorza from AstraZeneca
10th Dec 20185:59 pmRNSPosting of Shareholder Circular
10th Dec 201812:59 pmRNSProposed admission to trading on AIM
30th Nov 20187:00 amRNSTotal Voting Rights
31st Oct 20182:13 pmRNSTotal Voting Rights
25th Oct 20183:00 pmRNSHolding(s) in Company
28th Sep 20187:00 amRNSTotal Voting Rights
27th Sep 20187:00 amRNSInterim Results for Six Months Ended 30 June 2018
7th Sep 201811:36 amRNSNotice of Interim Results and Broker Appointment
3rd Sep 201812:15 pmRNSTotal Voting Rights
16th Aug 20184:25 pmRNSDirector Declaration
13th Aug 20187:00 amRNSRegulatory Application
31st Jul 20187:00 amRNSTotal Voting Rights
18th Jul 20184:14 pmRNSHolding(s) in Company
18th Jul 20184:12 pmRNSHolding(s) in Company
18th Jul 20184:11 pmRNSHolding(s) in Company
18th Jul 20181:52 pmRNSIssue of Equity and Total Voting Rights
16th Jul 20183:28 pmRNSResult of AGM
2nd Jul 20187:00 amRNSBlock listing Interim Review
29th Jun 20187:00 amRNSTotal Voting Rights
27th Jun 201812:23 pmRNSPublication of Circular
11th Jun 20184:20 pmRNSHolding(s) in Company
4th Jun 20184:18 pmRNSDirector/PDMR Shareholding
4th Jun 20184:15 pmRNSDirector/PDMR Shareholding
4th Jun 20184:14 pmRNSDirector/PDMR Shareholding
1st Jun 20187:00 amRNSUS Filing of Duaklir NDA & Tudorza Supplement NDA
31st May 20187:00 amRNSTotal Voting Rights
30th May 201812:05 pmRNSResult of AGM
22nd May 20187:00 amRNSPositive Data Presented at 2018 ATS Conference
18th May 201810:57 amRNSBlock listing Interim Review
14th May 20183:37 pmRNSHolding(s) in Company
30th Apr 20185:08 pmRNSTotal Voting Rights Update
27th Apr 20184:45 pmRNSAnnual Financial Report and Notice of AGM
26th Apr 20185:46 pmRNSHolding(s) in Company
26th Apr 20185:46 pmRNSHolding(s) in Company
24th Apr 20187:00 amRNSFinal Results
24th Apr 20187:00 amRNSIssue of Equity - AstraZeneca
12th Apr 20187:00 amRNSNotice of Results
29th Mar 20187:00 amRNSTotal Voting Rights
16th Mar 20184:40 pmRNSSecond Price Monitoring Extn
16th Mar 20184:35 pmRNSPrice Monitoring Extension
28th Feb 20182:01 pmRNSTotal Voting Rights
13th Feb 20187:00 amRNSDirectorate Change
8th Feb 20187:00 amRNSReceives Innovative Tech Contract from Vizient

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.